This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Jan. 7, 2013 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the leading owner, operator, and developer of high-quality, sustainable real estate for the broad and diverse life science industry, is pleased to announce that ARIAD Pharmaceuticals, Inc., a leading, fully integrated oncology company, will establish its state-of-the-art corporate and research and development headquarters at the Alexandria Center™ at Kendall Square in
Cambridge, Massachusetts. ARIAD has executed a 15-year lease with an affiliate of
Alexandria for approximately 244,000 rentable square feet, or 63%, of 75/125 Binney Street, an approximately 386,000 rentable square foot life science facility, with additional potential expansion opportunities through
June 30, 2014. ARIAD's decision to locate its headquarters at 75/125 Binney Street affirms the Alexandria Center at Kendall Square's reputation as one of the world's most desirable locations for life science innovation and collaboration.
75/125 Binney Street will facilitate ARIAD's continued discovery, development and commercialization activities in the oncology field. ARIAD's approximately 20-year track record of scientific excellence is based on the company's computational structure-based drug design platform, which has led to several internally discovered, molecularly targeted product candidates for drug-resistant or difficult-to-treat cancers. On
December 14, 2012, ARIAD announced that the United States Food and Drug Administration (FDA) approved its drug, Iclusig™ (ponatinib), three months ahead of the action date under the FDA's accelerated approval program. Iclusig was approved for the treatment of adult patients with chronic, accelerated, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI therapy.
"As ARIAD continues to expand its presence both here in
Massachusetts, as well as globally, we are pleased to be working with
Alexandria on the construction of our new headquarters, which is expected to open by the beginning of 2015," stated
Harvey J. Berger, M.D., Chairman and Chief Executive Officer of ARIAD. "Maintaining our corporate presence in
Cambridge reaffirms our commitment to this world-renowned life sciences community and continued collaboration with leading academic scientists in the greater
Cambridge area. We look forward to our new location in Kendall Square, not far from where we founded the Company."
"We are honored that ARIAD and its senior management team, all of whom we greatly admire, respect, and have known almost since the founding of the company, have chosen a long-term relationship with
Alexandria and the world-class 75/125 Binney Street facility for its headquarters location," said
Joel S. Marcus, Chairman, Chief Executive Officer, and Founder of
Alexandria. "ARIAD's corporate and R&D headquarters will powerfully complement the vibrant and collaborative ecosystem at the Alexandria Center at Kendall Square,
Cambridge's newest destination for breakthrough life science innovation and collaboration."
Alexandria expects to deliver the 75/125 Binney Street facility to ARIAD in the first quarter of 2015. Consistent with the company's strategy, as an investment-grade REIT, of diversifying and broadening its capital structure and matching specific sources of capital with specific uses,
Alexandria will fund this development beginning in 2013 on a "leverage-neutral basis."
75/125 Binney Street, the second ground-up development at the Alexandria Center at Kendall Square, will be an approximately 386,000 rentable square foot life science facility at the forefront of innovation and collaboration. The main façade features custom textured rainscreen panels and windows alternating in an artistic manner reminiscent of DNA patterns. Designed as two towers, the flagship facility is separated by multiple unique, architectural glass terraces purposefully designed to enhance collaboration. These elevated convergence spaces will span a pedestrian corridor between
Binney Street and the landscaped Rogers Street Park. The
City of Cambridge is also commencing the development of Rogers Street Park, which will provide a lush green space for
Alexandria's client tenants and the neighboring community.
Located in the heart of
Cambridge's internationally acclaimed Kendall Square innovation cluster, the Alexandria Center at Kendall Square will ultimately become an 11-acre, world-class science park featuring four ground-up first-in-class life science developments – 50 Binney Street, 75/125 Binney Street, 100 Binney Street, and 225 Binney Street – aggregating approximately 1.7 million rentable square feet of high-quality laboratory/office space, as well as new residential developments totaling approximately 200,000 rentable square feet. The first development, an approximately 305,000 rentable square foot build-to-suit for Biogen Idec, Inc. at 225 Binney Street, is currently under construction and is anticipated to be delivered in the fourth quarter of 2013. With a plethora of collaborative amenities including a two-acre landscaped park, world-class restaurants, state-of-the-art meeting and event spaces, high-quality hotels, and wellness centers, the Alexandria Center at Kendall Square provides leading life science entities with a unique opportunity to drive productivity, accelerate innovation, and recruit and retain the brightest scientific minds.
Alexandria is the dominant life science owner and operator in the
Greater Boston cluster with approximately 3.4 million rentable square feet of high-quality laboratory/office space located adjacent to world-renowned academic and medical institutions.
Alexandria currently serves approximately 100 life science client tenants in the
Greater Boston cluster including Abbott Laboratories, Biogen Idec Inc., Dana-Farber Cancer Institute, Inc., Eisai Co., Ltd., GlaxoSmithKline plc, the
Massachusetts Institute of Technology, Novartis AG, and UMass Memorial Health Care, Inc.